CRYO CELL INTERNATIONAL INC (CCEL)

Current Report Filed: 2026-05-08

Cryo-Cell received notice that NYSE Regulation accepted its compliance plan, allowing the company to remain listed on NYSE American through a plan period ending September 9, 2027, avoiding immediate delisting.
The company must regain full compliance with NYSE American continued listing standards by the September 9, 2027 deadline or face potential delisting proceedings, representing significant execution risk over the next 16 months.
NYSE Regulation's acceptance indicates the company's remediation strategy was deemed viable, but the stock will remain under heightened scrutiny with periodic reviews during the plan period, creating continued uncertainty for investors.

Quarterly Report Filed: 2026-04-14

The company has entered into a new licensing agreement with Duke University, which could provide access to new stem cell technologies and potentially expand the company's product offerings.
The company has obtained a revolving credit facility and term loan, which could provide additional financing flexibility to support its operations and growth initiatives.
The company has granted stock options with market-based vesting conditions to its co-CEOs and other key executives, potentially aligning their interests with shareholders.

Current Report Filed: 2026-03-12

Cryo-Cell International has received a notice from NYSE American indicating that the company is not in compliance with certain continued listing standards, which could result in delisting if the issue is not resolved.
The company has until April 8, 2026, to submit a plan to NYSE American outlining how it intends to regain compliance, but there is no assurance that the plan will be accepted or that the company will be able to regain compliance within the allotted time frame.
The company's common stock will continue to trade on the NYSE American under the symbol 'CCEL' while the company pursues a plan to regain compliance, but a delisting could have a significant impact on the stock's liquidity and accessibility for investors.

Annual Report Filed: 2026-02-27

The company has entered into a licensing agreement with Duke University to expand its umbilical cord blood and cord tissue stem cell service offerings, which could drive future growth.
The company has issued amended and restated promissory notes and made changes to its Susser Bank credit agreement, suggesting potential financing activities or debt restructuring.
The company has granted various stock options and restricted shares to its executives and employees, which could indicate changes in its compensation and incentive structure.

Insider Trading Filed: 2026-01-09

The reporting person, Jill M. Taymans, who is the VP Finance and CFO of Cryo-Cell International Inc. (CCEL), disposed of 45,396 shares of the company's common stock.
The reporting person was also granted 10,000 and 20,000 stock options with an exercise price of $3.54, which vest over a multi-year period and are subject to stock price performance conditions.
The insider transactions and option grants suggest continued executive involvement and confidence in the company's future performance.

Insider Trading Filed: 2026-01-09

Mark Portnoy, the Co-CEO and a 10% owner of Cryo-Cell International Inc, purchased 50,000 stock options and 25,000 stock options with an exercise price of $3.89 on January 7, 2026. This suggests Portnoy's confidence in the company's future performance.
The stock options granted to Portnoy are subject to both time-based vesting and stock price performance conditions, requiring the company's stock to reach certain price targets over the next few years. This aligns Portnoy's incentives with shareholders' long-term interests.
Portnoy also holds a significant direct and indirect ownership stake in Cryo-Cell, with over 935,000 shares beneficially owned. His substantial investment in the company's equity suggests he is deeply committed to the firm's success.

Insider Trading Filed: 2026-01-09

Oleg Mikulinsky, the Chief Information Officer of Cryo-Cell International Inc. (CCEL), has exercised 30,000 stock options with a strike price of $3.54 on January 7, 2026.
The options are divided into three equal tranches with time-based vesting and stock-price performance conditions, incentivizing Mikulinsky to drive the company's stock price higher.
This insider buying activity suggests Mikulinsky's confidence in the company's future prospects and aligns his interests with those of CCEL's shareholders.

Insider Trading Filed: 2026-01-09

David Portnoy, the Chairman and Co-CEO of Cryo-Cell International Inc (CCEL), has acquired a significant amount of CCEL stock through various means, including direct purchases, shares held through corporations, and shares held in retirement and personal accounts.
Portnoy has been granted several stock options with varying exercise prices and vesting schedules, indicating the company's efforts to incentivize and retain its top executive.
The vesting of some of the stock options is tied to the company's stock price reaching certain performance thresholds, aligning Portnoy's interests with those of other shareholders.

Important Information